Definitive Contract 75N95024C00026
Award Date
9/9/24
Potential Completion Date
9/8/25
Potential Value
$300K
Federal Agency
National Institute on Drug Abuse
Awardee
Guild Associates Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Dublin, OH 43016, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
5
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $300,000.00 Firm Fixed Price Definitive Contract awarded by the National Institute on Drug Abuse (NIDA), a component of the U.S. Department of Health and Human Services, to Base Pair Biotechnologies Inc., a small business concern, to develop aptasensors for measuring long-term adherence to tenofovir-based and long-acting HIV treatment regimens. The contract was awarded under the Small Business Innovation Research (SBIR) program, which is designed to stimulate technological...
Guild Associates Inc., doing business as Guild Biosciences, has been awarded a $299,971 firm fixed price Small Business Innovation Research Program Phase I contract from the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases. Under this contract, Guild Biosciences will conduct research and development of a point-of-care electrochemical aptasensor for long-term pharmacological adherence monitoring in support of the NIH and...
This is a $299,988 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Zymeron Corporation, a minority-owned small business. The contract is for the development of novel, low-cost, real-time point-of-care (POC) assays for HIV viral load monitoring, HIV drug resistance monitoring, and pharmacological adherence monitoring. This contract was awarded under the Small Business Innovation...
This is a $300,000.00 Firm Fixed Price Definitive Contract awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to Vala Sciences Inc. to conduct Small Business Innovation Research (SBIR) Phase I research and development on the "Development of Novel In-Vitro and In-Vivo Models to Support NeuroHIV Research." The contract was set aside for small businesses and has an ultimate completion date of September 26, 2025. Vala Sciences...
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases awarded a Small Business Innovation Research (SBIR) Program Phase II contract to Aldatu Biosciences, Inc. to develop an assay to detect minor populations of resistant HIV variants in blood specimens from infected individuals with viral loads above 1,000 copies/mL. The firm-fixed-price contract, valued at $2,980,467.00, was awarded on July 30, 2018 with a...
<p>The National Institute on Drug Abuse (NIDA), a civilian federal agency, awarded a $24,900 firm fixed price purchase order contract to Pelago Bioscience AB, a for-profit limited liability company. The contract is for the development of a new assay to test compounds of interest. The period of performance runs from the award date of September 9, 2024 through September 8, 2025. This contract award does not have a set-aside designation.</p>
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Darwin Biosciences, Inc., a minority-owned, woman-owned small business based in Broomfield, Colorado. The $299,408 firm-fixed-price contract is for the development of rapid diagnostic assays to aid in the self-monitoring of acute or rebound HIV-1 infection. The contract has an ultimate completion date of April 14, 2025. As an SBIR Phase I award,...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Virodx LLC, a minority-owned, woman-owned small business. The contract is for the development of a "METHOD FOR THE DETECTION OF MINORITY POPULATIONS OF DRUG RESISTANT HIV" and has a firm fixed price of $112,496.00 with a completion date of June 29, 2017. As this is an SBIR Phase I contract, the focus is on research...
<p>The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, awarded a Small Business Innovation Research (SBIR) Phase I contract to Aldatu Biosciences, Inc. for the development of a rapid, sensitive, and cost-effective method to detect drug-resistant HIV minority variants. The contract, valued at $298,690.00, is a Definitive Contract with a Firm Fixed Price pricing type. The contract has an ultimate completion date of December 14, 2017.</p>
<p>This is a $187,493.00 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Mogene Clinical Diagnostics, LC, a small disadvantaged business. The contract is for the development of a "METHOD FOR THE DETECTION OF MINORITY POPULATIONS OF DRUG RESISTANT HIV". The award was made on August 11, 2016 with a final completion date of June 14, 2017.</p>